The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status.
Evan Hersh
Research Funding - Celgene
Michele Del Vecchio
Research Funding - Bristol-Myers Squibb; Celgene; Novartis; Roche
Michael Paul Brown
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Richard Kefford
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Carmen Loquai
Consultant or Advisory Role - Celgene
Alessandro Testori
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Roche
Mingyu Li
Employment or Leadership Position - Celgene
Stock Ownership - Celgene (B)
Ileana Elias
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Markus F. Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche